Harmonisation of in-silico next-generation sequencing based methods for diagnostics and surveillance.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
23 08 2022
Historique:
received: 11 02 2022
accepted: 14 07 2022
entrez: 23 8 2022
pubmed: 24 8 2022
medline: 26 8 2022
Statut: epublish

Résumé

Improvements in cost and speed of next generation sequencing (NGS) have provided a new pathway for delivering disease diagnosis, molecular typing, and detection of antimicrobial resistance (AMR). Numerous published methods and protocols exist, but a lack of harmonisation has hampered meaningful comparisons between results produced by different methods/protocols vital for global genomic diagnostics and surveillance. As an exemplar, this study evaluated the sensitivity and specificity of five well-established in-silico AMR detection software where the genotype results produced from running a panel of 436 Escherichia coli were compared to their AMR phenotypes, with the latter used as gold-standard. The pipelines exploited previously known genotype-phenotype associations. No significant differences in software performance were observed. As a consequence, efforts to harmonise AMR predictions from sequence data should focus on: (1) establishing universal minimum to assess performance thresholds (e.g. a control isolate panel, minimum sensitivity/specificity thresholds); (2) standardising AMR gene identifiers in reference databases and gene nomenclature; (3) producing consistent genotype/phenotype correlations. The study also revealed limitations of in-silico technology on detecting resistance to certain antimicrobials due to lack of specific fine-tuning options in bioinformatics tool or a lack of representation of resistance mechanisms in reference databases. Lastly, we noted user friendliness of tools was also an important consideration. Therefore, our recommendations are timely for widespread standardisation of bioinformatics for genomic diagnostics and surveillance globally.

Identifiants

pubmed: 35999234
doi: 10.1038/s41598-022-16760-9
pii: 10.1038/s41598-022-16760-9
pmc: PMC9396611
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14372

Informations de copyright

© 2022. Crown.

Références

Front Microbiol. 2020 May 25;11:861
pubmed: 32523560
Genome Biol. 2016 Nov 25;17(1):239
pubmed: 27887629
EFSA J. 2019 Jun 05;17(6):e05709
pubmed: 32626332
Microb Genom. 2020 Feb;6(2):
pubmed: 32048983
Microb Genom. 2021 Oct;7(10):
pubmed: 34609275
Microb Genom. 2022 Mar;8(3):
pubmed: 35344479
J Antimicrob Chemother. 2020 Dec 1;75(12):3491-3500
pubmed: 32780112
Microb Genom. 2017 Sep 4;3(10):e000131
pubmed: 29177089
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Front Microbiol. 2018 Mar 27;9:592
pubmed: 29636749
PLoS One. 2015 Aug 05;10(8):e0135010
pubmed: 26244504
J Mol Diagn. 2015 Nov;17(6):623-34
pubmed: 26433313
F1000Res. 2018 Apr 13;7:459
pubmed: 30026930
Euro Surveill. 2019 Dec;24(50):
pubmed: 31847943
Int J Antimicrob Agents. 2012 Apr;39(4):273-82
pubmed: 22230333
Microbiology (Reading). 2009 Oct;155(Pt 10):3200-3213
pubmed: 19574306
Sci Rep. 2020 Nov 16;10(1):19880
pubmed: 33199763
Int J Infect Dis. 2021 Feb;103:305-307
pubmed: 33333251
Front Public Health. 2019 Sep 04;7:242
pubmed: 31552211
J Antimicrob Chemother. 2017 Oct 1;72(10):2764-2768
pubmed: 29091202
Genome Res. 2020 Jan;30(1):138-152
pubmed: 31809257
Clin Vaccine Immunol. 2006 May;13(5):561-7
pubmed: 16682477
Res Vet Sci. 2009 Feb;86(1):27-35
pubmed: 18585745
Front Microbiol. 2021 Apr 01;12:626774
pubmed: 33868190
J Antimicrob Chemother. 2017 Mar 1;72(3):691-695
pubmed: 27999032
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30885899
Euro Surveill. 2008 May 08;13(19):
pubmed: 18761982
Lancet Infect Dis. 2020 Nov;20(11):1263-1272
pubmed: 32679081
Front Microbiol. 2016 Jul 11;7:1057
pubmed: 27462301

Auteurs

J Nunez-Garcia (J)

Animal and Plant Health Agency (APHA), Weybridge, UK.

M AbuOun (M)

Animal and Plant Health Agency (APHA), Weybridge, UK.

N Storey (N)

Animal and Plant Health Agency (APHA), Weybridge, UK.

M S Brouwer (MS)

Wageningen Bioveterinary Research (WBVR), Lelystad, The Netherlands.

J F Delgado-Blas (JF)

Universidad Complutense de Madrid (UCM), Madrid, Spain.

S S Mo (SS)

Norwegian Veterinary Institute (NVI), Oslo, Norway.

N Ellaby (N)

Public Health England (PHE), London, UK.

K T Veldman (KT)

Wageningen Bioveterinary Research (WBVR), Lelystad, The Netherlands.

M Haenni (M)

Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Unité Antibiorésistance et Virulence Bactériennes, Maisons-Alfort, France.

P Châtre (P)

Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Unité Antibiorésistance et Virulence Bactériennes, Maisons-Alfort, France.

J Y Madec (JY)

Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Unité Antibiorésistance et Virulence Bactériennes, Maisons-Alfort, France.

J A Hammerl (JA)

German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

C Serna (C)

Universidad Complutense de Madrid (UCM), Madrid, Spain.

M Getino (M)

University of Surrey (UoS), Guildford, UK.

R La Ragione (R)

University of Surrey (UoS), Guildford, UK.

T Naas (T)

Assistance Publique Hopitaux de Paris, Paris, France.

A A Telke (AA)

Norwegian Veterinary Institute (NVI), Oslo, Norway.

P Glaser (P)

Institute Pasteur, EERA Unit, Paris, France.

M Sunde (M)

Norwegian Veterinary Institute (NVI), Oslo, Norway.

B Gonzalez-Zorn (B)

Universidad Complutense de Madrid (UCM), Madrid, Spain.

M J Ellington (MJ)

Public Health England (PHE), London, UK.

M F Anjum (MF)

Animal and Plant Health Agency (APHA), Weybridge, UK. muna.anjum@apha.gov.uk.
University of Surrey (UoS), Guildford, UK. muna.anjum@apha.gov.uk.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH